NCT07544056 2026-04-22A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast CancerBeBetter Med IncPhase 2/3 Not yet recruiting446 enrolled
NCT06926868 2026-04-01A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)Bristol-Myers SquibbPhase 2/3 Recruiting500 enrolled